Literature DB >> 25806335

A phase I study of MEDI4736, NNT-PD-L1 antibody in patients with advanced solid tumors.

Christoph C Zielinski1.   

Abstract

A review and critical consideration of immunotherapeutical concepts in non-small cell lung cancer (NSCLC) is given. Nivolumab represents a promising option in various malignancies with more results exceeding treatment of metastatic malignant melanoma eagerly awaited.

Entities:  

Keywords:  Immunotherapy; lung cancer; nivolumab

Year:  2014        PMID： 25806335      PMCID： PMC4367668          DOI： 10.3978/j.issn.2218-6751.2014.08.07

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


  11 in total

1.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

Review 2.  Immunosuppressive networks in the tumour environment and their therapeutic relevance.

Authors:  Weiping Zou
Journal:  Nat Rev Cancer       Date:  2005-04       Impact factor: 60.716

Review 3.  Cancer immunotherapy comes of age.

Authors:  Ira Mellman; George Coukos; Glenn Dranoff
Journal:  Nature       Date:  2011-12-21       Impact factor: 49.962

4.  Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

Authors:  Thomas J Lynch; Igor Bondarenko; Alexander Luft; Piotr Serwatowski; Fabrice Barlesi; Raju Chacko; Martin Sebastian; Joel Neal; Haolan Lu; Jean-Marie Cuillerot; Martin Reck
Journal:  J Clin Oncol       Date:  2012-04-30       Impact factor: 44.544

5.  Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

Authors:  Suzanne L Topalian; Mario Sznol; David F McDermott; Harriet M Kluger; Richard D Carvajal; William H Sharfman; Julie R Brahmer; Donald P Lawrence; Michael B Atkins; John D Powderly; Philip D Leming; Evan J Lipson; Igor Puzanov; David C Smith; Janis M Taube; Jon M Wigginton; Georgia D Kollia; Ashok Gupta; Drew M Pardoll; Jeffrey A Sosman; F Stephen Hodi
Journal:  J Clin Oncol       Date:  2014-03-03       Impact factor: 44.544

Review 6.  Immune surveillance: a balance between protumor and antitumor immunity.

Authors:  Suzanne Ostrand-Rosenberg
Journal:  Curr Opin Genet Dev       Date:  2008-03-04       Impact factor: 5.578

7.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

8.  Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer.

Authors:  Mario Sznol; Lieping Chen
Journal:  Clin Cancer Res       Date:  2013-03-01       Impact factor: 12.531

Review 9.  Hallmarks of cancer: the next generation.

Authors:  Douglas Hanahan; Robert A Weinberg
Journal:  Cell       Date:  2011-03-04       Impact factor: 41.582

Review 10.  Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion.

Authors:  Robert D Schreiber; Lloyd J Old; Mark J Smyth
Journal:  Science       Date:  2011-03-25       Impact factor: 47.728
View more
  14 in total

Review 1.  Trial Watch: Immunotherapy plus radiation therapy for oncological indications.

Authors:  Erika Vacchelli; Norma Bloy; Fernando Aranda; Aitziber Buqué; Isabelle Cremer; Sandra Demaria; Alexander Eggermont; Silvia Chiara Formenti; Wolf Hervé Fridman; Jitka Fucikova; Jérôme Galon; Radek Spisek; Eric Tartour; Laurence Zitvogel; Guido Kroemer; Lorenzo Galluzzi
Journal:  Oncoimmunology       Date:  2016-07-25       Impact factor: 8.110

Review 2.  Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease.

Authors:  Steven S Yu; Tanya B Dorff; Leslie K Ballas; Sarmad Sadeghi; Eila C Skinner; David I Quinn
Journal:  Clin Adv Hematol Oncol       Date:  2017-06

Review 3.  Immunotherapy in urothelial cancer, part 2: adjuvant, neoadjuvant, and adjunctive treatment.

Authors:  Steven S Yu; Leslie K Ballas; Eila C Skinner; Tanya B Dorff; Sarmad Sadeghi; David I Quinn
Journal:  Clin Adv Hematol Oncol       Date:  2017-07

Review 4.  Optimized Dosing: The Next Step in Precision Medicine in Non-Small-Cell Lung Cancer.

Authors:  René J Boosman; Jacobus A Burgers; Egbert F Smit; Neeltje Steeghs; Anthonie J van der Wekken; Jos H Beijnen; Alwin D R Huitema; Rob Ter Heine
Journal:  Drugs       Date:  2021-12-11       Impact factor: 9.546

Review 5.  Cancer stem cells in small cell lung cancer.

Authors:  Jordi Codony-Servat; Alberto Verlicchi; Rafael Rosell
Journal:  Transl Lung Cancer Res       Date:  2016-02

Review 6.  Anti-PD-1/PD-L1 therapy of human cancer: past, present, and future.

Authors:  Lieping Chen; Xue Han
Journal:  J Clin Invest       Date:  2015-09-01       Impact factor: 14.808

Review 7.  PD-1 inhibition and treatment of advanced melanoma-role of pembrolizumab.

Authors:  Ali R Jazirehi; Alexandra Lim; Tam Dinh
Journal:  Am J Cancer Res       Date:  2016-10-01       Impact factor: 6.166

8.  High PD-L1 expression was associated with poor prognosis in 870 Chinese patients with breast cancer.

Authors:  Tao Qin; Yin-duo Zeng; Ge Qin; Fei Xu; Jia-bin Lu; Wen-feng Fang; Cong Xue; Jian-hua Zhan; Xin-ke Zhang; Qiu-fan Zheng; Rou-jun Peng; Zhong-yu Yuan; Li Zhang; Shu-sen Wang
Journal:  Oncotarget       Date:  2015-10-20

Review 9.  PD-1 and its ligands are important immune checkpoints in cancer.

Authors:  Yinan Dong; Qian Sun; Xinwei Zhang
Journal:  Oncotarget       Date:  2017-01-10

Review 10.  Current status and perspectives in immunotherapy for metastatic melanoma.

Authors:  Riccardo Marconcini; Francesco Spagnolo; Luigia Stefania Stucci; Simone Ribero; Elena Marra; Francesco De Rosa; Virginia Picasso; Lorenza Di Guardo; Carolina Cimminiello; Stefano Cavalieri; Laura Orgiano; Enrica Tanda; Laura Spano; Alfredo Falcone; Paola Queirolo
Journal:  Oncotarget       Date:  2018-01-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.